Literature DB >> 22911632

Comparison of the structural stability and dynamic properties of recombinant anthrax protective antigen and its 2-fluorohistidine-labeled analogue.

Lei Hu1, Sangeeta B Joshi, Kiran K Andra, Santosh V Thakkar, David B Volkin, James G Bann, C Russell Middaugh.   

Abstract

Protective antigen (PA) is the primary protein antigenic component of both the currently used anthrax vaccine and related recombinant vaccines under development. An analogue of recombinant PA (2-FHis rPA) has been recently shown to block the key steps of pore formation in the process of inducing cytotoxicity in cells, and thus can potentially be used as an antitoxin or a vaccine. This rPA analogue was produced by fermentation to incorporate the unnatural amino acid 2-fluorohistidine (2-FHis). In this study, the effects of 2-FHis labeling on rPA antigen's conformational stability and dynamic properties were investigated by various biophysical techniques. Temperature/pH stability profiles of rPA and 2-FHis rPA were analyzed by the empirical phase diagram (EPD) approach, and physical stability differences between them were identified. Results showed that rPA and 2-FHis rPA had similar stability at pH 7-8. With decreasing solution pH, however, 2-FHis rPA was found to be more stable. Dynamic sensitive measurements of the two proteins at pH 5 found that 2-FHis rPA was more dynamic and/or differentially hydrated under acidic pH conditions. The biophysical characterization and stability data provide information useful for the potential development of 2-FHis rPA as a more stable rPA vaccine candidate.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22911632      PMCID: PMC3798070          DOI: 10.1002/jps.23294

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  36 in total

Review 1.  Towards the nonstick egg: designing fluorous proteins.

Authors:  E Neil; G Marsh
Journal:  Chem Biol       Date:  2000-07

2.  The lethal and edema factors of anthrax toxin bind only to oligomeric forms of the protective antigen.

Authors:  Jeremy Mogridge; Kristina Cunningham; D Borden Lacy; Michael Mourez; R John Collier
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

3.  Exchange characteristics of calcium ions bound to anthrax protective antigen.

Authors:  Samantha Gao-Sheridan; Sen Zhang; R John Collier
Journal:  Biochem Biophys Res Commun       Date:  2003-01-03       Impact factor: 3.575

4.  Solution structure, dynamics, and thermodynamics of the native state ensemble of the Sem-5 C-terminal SH3 domain.

Authors:  Josephine C Ferreon; David E Volk; Bruce A Luxon; David G Gorenstein; Vincent J Hilser
Journal:  Biochemistry       Date:  2003-05-20       Impact factor: 3.162

Review 5.  The use of circular dichroism in the investigation of protein structure and function.

Authors:  S M Kelly; N C Price
Journal:  Curr Protein Pept Sci       Date:  2000-12       Impact factor: 3.272

6.  Derivative absorbance spectroscopy and protein phase diagrams as tools for comprehensive protein characterization: a bGCSF case study.

Authors:  Lisa A Kueltzo; Baran Ersoy; John P Ralston; C Russell Middaugh
Journal:  J Pharm Sci       Date:  2003-09       Impact factor: 3.534

Review 7.  Anthrax as a biological weapon, 2002: updated recommendations for management.

Authors:  Thomas V Inglesby; Tara O'Toole; Donald A Henderson; John G Bartlett; Michael S Ascher; Edward Eitzen; Arthur M Friedlander; Julie Gerberding; Jerome Hauer; James Hughes; Joseph McDade; Michael T Osterholm; Gerald Parker; Trish M Perl; Philip K Russell; Kevin Tonat
Journal:  JAMA       Date:  2002-05-01       Impact factor: 56.272

8.  Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor.

Authors:  Heather M Scobie; G Jonah A Rainey; Kenneth A Bradley; John A T Young
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-16       Impact factor: 11.205

9.  Identification of the cellular receptor for anthrax toxin.

Authors:  K A Bradley; J Mogridge; M Mourez; R J Collier; J A Young
Journal:  Nature       Date:  2001-11-08       Impact factor: 49.962

Review 10.  Anthrax toxin.

Authors:  R John Collier; John A T Young
Journal:  Annu Rev Cell Dev Biol       Date:  2003       Impact factor: 13.827

View more
  4 in total

1.  High-throughput biophysical analysis and data visualization of conformational stability of an IgG1 monoclonal antibody after deglycosylation.

Authors:  Mohammad A Alsenaidy; Jae Hyun Kim; Ranajoy Majumdar; David D Weis; Sangeeta B Joshi; Thomas J Tolbert; C Russell Middaugh; David B Volkin
Journal:  J Pharm Sci       Date:  2013-09-24       Impact factor: 3.534

2.  Biophysical characterization and immunization studies of dominant negative inhibitor (DNI), a candidate anthrax toxin subunit vaccine.

Authors:  Vidyashankara Iyer; Lei Hu; Carole E Schanté; David Vance; Chrystal Chadwick; Nishant Kumar Jain; Robert N Brey; Sangeeta B Joshi; David B Volkin; Kiran K Andra; James G Bann; Nicholas J Mantis; C Russell Middaugh
Journal:  Hum Vaccin Immunother       Date:  2013-08-07       Impact factor: 3.452

3.  The Biophysical Probes 2-fluorohistidine and 4-fluorohistidine: Spectroscopic Signatures and Molecular Properties.

Authors:  Chandana Kasireddy; Jonathan M Ellis; James G Bann; Katie R Mitchell-Koch
Journal:  Sci Rep       Date:  2017-02-15       Impact factor: 4.379

4.  A single-dose PLGA encapsulated protective antigen domain 4 nanoformulation protects mice against Bacillus anthracis spore challenge.

Authors:  Manish Manish; Amit Rahi; Manpreet Kaur; Rakesh Bhatnagar; Samer Singh
Journal:  PLoS One       Date:  2013-04-29       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.